Ironwood partner to build up and commercialize novel anti-anxiety compound Ironwood Pharmaceuticals.

Bionomics, Ironwood partner to build up and commercialize novel anti-anxiety compound Ironwood Pharmaceuticals, Inc. and Bionomics Small today announced that they entered right into a collaboration, analysis, and licensing contract which will enable Ironwood to build up and commercialize Bionomics’ investigational anti-anxiety compound BNC210 and other related substances more here . The purpose of the collaboration is normally to judge the compound’s potential as a novel anti-stress treatment. Data from many preclinical research indicate that BNC210 has anti-stress and anxiety activity without the sedative unwanted effects that are standard of benzodiazepines, a course of medicines used to treat nervousness.

Other entries from category "ozone therapy":

Random entries